Cambridge Antibody Technology Group PLC Takeover Gives Genzyme Corporation Buyout Rights To Drug

LONDON, May 15 (Reuters) - AstraZeneca's (AZN.L: Quote, Profile, Research) agreed takeover of Cambridge Antibody Technology (CAT.L: Quote, Profile, Research) will trigger a change of control clause that gives Genzyme (GENZ.O: Quote, Profile, Research) the option to buy out rights to a jointly developed experimental lung drug.

Back to news